PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23.48 Million EUR | -10201.75% |
| 2022 | -228 Thousand EUR | 99.58% |
| 2021 | -53.79 Million EUR | 26.61% |
| 2020 | -73.3 Million EUR | -16.98% |
| 2019 | -62.65 Million EUR | -63.93% |
| 2018 | -38.22 Million EUR | -14.0% |
| 2017 | -33.53 Million EUR | -52.33% |
| 2016 | -22.01 Million EUR | -46.62% |
| 2015 | -15.01 Million EUR | -69.45% |
| 2014 | -8.86 Million EUR | -8.78% |
| 2013 | -8.14 Million EUR | -274.98% |
| 2012 | -2.17 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.31 Million EUR | 4.99% |
| 2024 Q2 | -5.31 Million EUR | 0.0% |
| 2023 Q2 | -12.2 Million EUR | -100.0% |
| 2023 FY | -23.48 Million EUR | -10201.75% |
| 2023 Q3 | -5.69 Million EUR | 53.36% |
| 2023 Q4 | -5.59 Million EUR | 1.63% |
| 2023 Q1 | -6.1 Million EUR | -866.39% |
| 2022 Q3 | -5.13 Million EUR | -401.86% |
| 2022 FY | -228 Thousand EUR | 99.58% |
| 2022 Q4 | 796 Thousand EUR | 115.49% |
| 2022 Q2 | -1.02 Million EUR | 91.4% |
| 2022 Q1 | -11.91 Million EUR | 53.91% |
| 2021 Q3 | -13.63 Million EUR | 51.23% |
| 2021 FY | -53.79 Million EUR | 26.61% |
| 2021 Q4 | -25.84 Million EUR | -89.59% |
| 2021 Q1 | -11.94 Million EUR | 68.84% |
| 2021 Q2 | -27.95 Million EUR | -134.01% |
| 2020 Q4 | -38.33 Million EUR | -106.22% |
| 2020 FY | -73.3 Million EUR | -16.98% |
| 2020 Q1 | -17.58 Million EUR | 47.3% |
| 2020 Q2 | -34.96 Million EUR | -98.77% |
| 2020 Q3 | -18.59 Million EUR | 46.83% |
| 2019 Q1 | -11.66 Million EUR | -36.02% |
| 2019 Q2 | -29.28 Million EUR | -151.08% |
| 2019 FY | -62.65 Million EUR | -63.93% |
| 2019 Q4 | -33.37 Million EUR | -138.89% |
| 2019 Q3 | -13.97 Million EUR | 52.3% |
| 2018 Q4 | -8.57 Million EUR | 19.7% |
| 2018 Q3 | -10.67 Million EUR | -47.81% |
| 2018 Q2 | -7.22 Million EUR | 38.48% |
| 2018 Q1 | -11.74 Million EUR | 7.61% |
| 2018 FY | -38.22 Million EUR | -14.0% |
| 2017 Q4 | -12.71 Million EUR | -88.69% |
| 2017 Q1 | -6.52 Million EUR | -12.82% |
| 2017 Q2 | -7.55 Million EUR | -15.87% |
| 2017 FY | -33.53 Million EUR | -52.33% |
| 2017 Q3 | -6.73 Million EUR | 10.86% |
| 2016 Q2 | -6.02 Million EUR | -39.28% |
| 2016 Q4 | -5.78 Million EUR | 0.0% |
| 2016 Q3 | -5.78 Million EUR | 4.02% |
| 2016 FY | -22.01 Million EUR | -46.62% |
| 2016 Q1 | -4.32 Million EUR | -2.0% |
| 2015 Q4 | -4.24 Million EUR | 0.0% |
| 2015 Q3 | -4.24 Million EUR | -29.8% |
| 2015 FY | -15.01 Million EUR | -69.45% |
| 2015 Q2 | -3.26 Million EUR | 0.0% |
| 2015 Q1 | -3.26 Million EUR | -15.1% |
| 2014 Q4 | -2.83 Million EUR | 0.0% |
| 2014 Q1 | -1.59 Million EUR | 22.13% |
| 2014 Q3 | -2.83 Million EUR | -78.26% |
| 2014 Q2 | -1.59 Million EUR | 0.0% |
| 2014 FY | -8.86 Million EUR | -8.78% |
| 2013 FY | -8.14 Million EUR | -274.98% |
| 2013 Q2 | -2.02 Million EUR | 0.0% |
| 2013 Q3 | -2.04 Million EUR | -0.81% |
| 2013 Q1 | -2.02 Million EUR | -302.19% |
| 2013 Q4 | -2.04 Million EUR | 0.0% |
| 2012 Q4 | 1 Million EUR | 0.0% |
| 2012 FY | -2.17 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Boiron SA | 35.82 Million EUR | 165.559% |
| Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 113.789% |
| Vetoquinol SA | 55.56 Million EUR | 142.275% |
| Valneva SE | -101.42 Million EUR | 76.843% |
| AB Science S.A. | -10.04 Million EUR | -133.758% |
| Nanobiotix S.A. | -39.7 Million EUR | 40.836% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 17.127% |
| BioSenic S.A. | -28.77 Million EUR | 18.382% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 84.102% |
| Formycon AG | 75.79 Million EUR | 130.989% |